Development of an Oncogenic Driver Alteration Associated Immune-Related Prognostic Model for Stage I-II Lung Adenocarcinoma
Authors:
- Jian-Zhao XuJXJian-Zhao Xu
- Chen GongCGChen Gong
- Hua ZhaoHZHua Zhao
Open Access
- 28 January 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 10
Abstract
Lung adenocarcinoma (LUAD) needs to be stratified for its heterogeneity. Oncogenic driver alterations such asEGFRmutation,ALKtranslocation,ROS1translocation, andBRAFmutation predict response to treatment for LUAD. Since oncogenic driver alterations may modulate immune response in tumor microenvironment that may influence prognosis in LUAD, the effects ofEGFR,ALK,ROS1, andBRAFalterations on tumor microenvironment remain unclear. Immune-related prognostic model associated with oncogenic driver alterations is needed. In this study, we performed the Cox-proportional Hazards Analysis based on the L1-penalized (LASSO) Analysis to establish an immune-related prognostic model (IPM) in stage I-II LUAD patients, which was based on 3 immune-related genes (PDE4B,RIPK2, andIFITM1) significantly enriched in patients withoutEGFR,ALK,ROS1, andBRAFalterations in The Cancer Genome Atlas (TCGA) database. Then, patients were categorized into high-risk and low-risk groups individually according to the IPM defined risk score. The predicting ability of the IPM was validated in GSE31210 and GSE26939 downloaded from the Gene Expression Omnibus (GEO) database. High-risk was significantly associated with lower overall survival (OS) rates in 3 independent stage I-II LUAD cohorts (allP< 0.05). Moreover, the IPM defined risk independently predicted OS for patients in TCGA stage I-II LUAD cohort (P= 0.011). High-risk group had significantly higher proportions of macrophages M1 and activated mast cells but lower proportions of memory B cells, resting CD4 memory T cells and resting mast cells than low-risk group (allP< 0.05). In addition, the high-risk group had a significantly lower expression ofCTLA-4,PDCD1,HAVCR2, andTIGITthan the low-risk group (allP< 0.05). In summary, we established a novel IPM that could provide new biomarkers for risk stratification of stage I-II LUAD patients.Keywords
This publication has 70 references indexed in Scilit:
- Hallmarks of Cancer: The Next GenerationCell, 2011
- PDE4 inhibition drives resolution of neutrophilic inflammation by inducing apoptosis in a PKA-PI3K/Akt-dependent and NF-κB-independent mannerJournal of Leukocyte Biology, 2010
- Suppression of LPS-Induced TNF-α Production in Macrophages by cAMP Is Mediated by PKA-AKAP95-p105Science Signaling, 2009
- Inhibitory B7-family molecules in the tumour microenvironmentNature Reviews Immunology, 2008
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct MechanismsMolecular and Cellular Biology, 2005
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences, 2005
- The Three Es of Cancer ImmunoeditingAnnual Review of Immunology, 2004
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002
- CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.Journal of Experimental Medicine, 1995